Newsroom | 61244 results

BRISBANE, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of severe bone and connective tissue disorders, today announced that the first participant has been dosed in its Phase 1b clinical trial of andecaliximab in patients with spinal cord injury (SCI). The study, called ANDECA-HO, is evaluating patients who are at risk of developing heterotopic ossification (HO), a condition that causes abnormal bone form...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board...

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy's new study shows its FDA-approved ColoSense offers strong clinical benefits for CRC screening when modeled at real-world adherence levels....

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Platinum® Pro Instrument Placed at the Broad Institute to Support Regional Research Initiatives...

SAN FRANCISCO--(BUSINESS WIRE)--Xcell Biosciences (Xcellbio), a San Francisco-based instrumentation company focused on cell and gene therapy applications, today announced a strategic collaboration with Thermo Fisher Scientific Inc., the world leader in serving science, to advance research in regulatory T cells (Tregs) and tumor-infiltrating lymphocytes (TILs). While significant progress has been made in the cell therapy space leveraging Chimeric Antigen Receptor T (CAR T) cells, this collaborat...

SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, today announces it has been named the Fierce CRO Award winner in the Excellence in Global Operations category by Fierce Biotech. The Fierce CRO Awards celebrate exceptional achievements and innovations by Contract Research Organizations, recognizing CROs demonstrating outstanding performance, innovation, and...

KIRKLAND, Wash.--(BUSINESS WIRE)--Verasonics, Inc., the leader in research ultrasound, today announced a partnership with PhotoSound® Technologies, Inc. of Houston, TX to offer customers the PhotoSound Legion™ AMP for use with Vantage® and Vantage NXT Research Ultrasound Systems. Partnership will offer Vantage customers expanded capabilities by integrating the Legion AMP128 in applications using photoacoustic imaging, thermoacoustic imaging, and monitoring radiation therapy, among others. The L...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, today announced the closing of a $96.5 million Series D financing round led by a healthcare investor, with significant support from existing investors Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman) Ltd., an...

AUSTIN, Texas--(BUSINESS WIRE)--ImmunoPrecise (NASDAQ: IPA), a leader in AI-driven biotherapeutics, provides a significant update following its June 5, 2025, press release ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery. This new release details the downstream validation of the epitope identified in that initial announcement—demonstrating that the computationally selected vaccine target is not only highly conserved across all four dengue virus types but also...

MADISON, Wis.--(BUSINESS WIRE)--Drug discovery researchers can connect with Promega TRS on two major procurement platforms, streamlining access to custom assay development....